In Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC, the Federal Circuit jumped on the bandwagon ...

The Federal Circuit's recent ruling that patents listed in the FDA's Orange Book must cover the active ingredient of a drug has sparked significant debate in the pharmaceutical industry. The court's ...

The US Court of Appeals for the Federal Circuit affirmed a district court’s delisting of patents from the Orange Book because the patent claims ...

William B. Feldman, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues compared the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice-daily metered dose ...

Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.

Xiaomi has unveiled its latest offering, the Mijia Top-Flow Pro Air Conditioner, in a sleek Crystal White finish for the Chinese market. Priced competitively at 3,699 yuan ($506), the air ...

Objective To compare the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once daily dry powder inhaler, ...

Asthma inhalers are hand-held devices that allow you to inhale ... These include Ventolin HFA, Proventil HFA, Proair HFA, Atrovent HFA, Alvesco HFA, and Asmanex HFA. AirSupra is also an MDI. To ensure ...

HFA-based metered-dose inhalers (MDIs ... You should finish it or run out by 30 days. Some inhaler devices, such as ProAir Digihaler, are Bluetooth linked to a companion mobile app, so it will alert ...

ProAir HFA inhaler from the Food and Drug Administration’s Orange Book. Amneal plans to market a generic version of the inhaler and had argued that Teva’s patents were incorrectly included on ...

U.S. District Judge Stanley Chesler agreed with Amneal in June, finding the patents only cover parts of an inhaler device and "do not claim or even mention" ProAir HFA's active ingredient.

2024 Teva Pharmaceuticals failed to convince a U.S. appeals court on Friday to reverse a decision that would remove patents related to its ProAir HFA inhaler from the U.S. Food and Drug ...